NEW YORK (GenomeWeb News) – Epigenetics-based cancer test developer PrognosDx has named Joseph Vallner to be its new CEO. Vallner, who formerly was president and COO at Cell Genesys, will succeed founding President and CEO Kamran Tahamtanzadeh, who will continue to serve as chairman of the board of directors.

The company is preparing to launch its PrognoScore test to predict clinical outcomes and assess risk probabilities for prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.